Many clinical trials have shown that the addition of PD-(L)1 inhibitors to chemotherapy can not only prolong the OS and PFS of patients with NSCLC but also reduce the incidence of adverse reactions (11–14). The gene discussed is CD274; the disease is non-small cell lung carcinoma.